Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in STEMI Patients with LV Dysfunction
NCT05045274Unknown
- Sponsor
- Assiut University
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of dapagliflozin in ST elevation myocardial infarction (STEMI) and left ventricular systolic dysfunction (LVSD) (2 arms), sponsored by Assiut University. Primary endpoint: Improvement in Left Ventricular Ejection Fraction at 3 months. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
ST elevation myocardial infarction (STEMI)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on NCT05045274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05045274.